Table 3 Treatment specifications
Factor | Recommendations |
|---|---|
Recommended Imaging before therapeutic decision | 93% PSMA PET/CT |
64% pelvic multiparametric MRI | |
further: bone scan, PSMA-PET MRI, choline PET (1 center each) | |
Dose to elective pelvic lymph nodes (ENRT) | Median dose 50 Gy (range, 45–54 Gy) in 1.8–2 Gy/fraction |
No pelvic RT recommended by 14% | |
Prostate bed RT | Always included by 58% of the centers using pelvic RT |
Median dose 66 Gy (range, 64–70 Gy) | |
Dose for lymph node boost for pelvic RT | SIB in 75%, median dose 66 Gy (range 57.5–70 Gy, single dose 2–2.5 Gy) |
SBRT boost in 25% (2 × 5 Gy) | |
SBRT* | 29% 3-fraction course (SD 10–15 Gy) |
43% 5-fraction course (SD 6–8 Gy) | |
14% > 10 fraction course (SD 3.5 Gy) | |
36% no primary SBRT | |
Margins SBRT | CTV, median 0 mm (range, 0–5 mm) |
PTV, median 5 mm (range, 3–5 mm) | |
Recommendation for concomitant ADT | standard duration 57% six months, 7% nine months |
21% in the presence of risk factors 6–24 months | |
29% no concomitant ADT (in addition to SBRT) |